Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
Hepatitis B testing should be done before hepatitis C treatment due to risk of HBV reactivation

People considering direct-acting antiviral (DAA) therapy for hepatitis C should first be tested for hepatitis B virus (HBV) and monitored throughout therapy, as elimination of hepatitis C virus

Published
07 October 2016
By
Liz Highleyman
European regulator amends some Gilead hep C patent claims

In a setback for Gilead Sciences, European regulators decided not to uphold all of its patent claims for the best-selling Sovaldi hepatitis C treatment, a move that could lead to generic versions of the medicine becoming available four years sooner than had been expected.

Published
06 October 2016
From
STAT
HCV Drugs May Reactivate HBV, FDA Warns

Patients with a past or current hepatitis B virus (HBV) infection can experience sometimes fatal HBV reactivation if they take any of nine direct-acting antivirals for hepatitis virus C (HCV) infection, the US Food and Drug Administration (FDA) announced today.

Published
06 October 2016
From
Medscape (free registration required)
100% cure rate for people with HCV genotype 1 treated with AL-335, odalasvir and simeprevir for 6 or 8 weeks

A triple regimen containing two experimental hepatitis C drugs – AL-335 and odalasvir – plus simeprevir taken for either 6 or 8 weeks cured all participants with

Published
05 October 2016
By
Liz Highleyman
UNITAID and FIND launch initiative to improve diagnostics and treatment for hepatitis C

The US $38.3 million project will support the development of better, simpler, diagnostic tools for HCV where people seek care, and will introduce HCV testing and treatment over three and a half years in HIV programmes in seven countries: Cameroon, Georgia, India, Malaysia, Myanmar, Thailand and Vietnam.

Published
04 October 2016
From
UNITAID
Elimination of viral hepatitis by 2030: What's needed and how do we get there?

This first European Action Plan provides an important driver to aid countries in their fight against viral hepatitis, to which ECDC had the opportunity to contribute directly. Currently, the available surveillance data show ongoing transmission of hepatitis in Europe and in order to interrupt this chain and to prevent further infections, European countries need to strengthen local prevention and control practices as outlined in the plan.

Published
04 October 2016
From
European Centre for Disease Prevention and Control (ECDC)
Hepatitis C infection and reinfection among men who have sex with men need higher priority, US and European studies show

Public health officials in Michigan have identified a cluster of more than 20 cases of apparently sexually transmitted hepatitis C virus (HCV) infection among HIV-positive gay and

Published
30 September 2016
By
Liz Highleyman
Australia leading world in hepatitis C treatment; but disease more prevalent in Aboriginal people

More people are on track to be cured of hepatitis C in Australia this year than over the past two decades combined, new research has shown.

Published
29 September 2016
From
ABC Online
Risk of reinfection is a concern after successful hepatitis C treatment

People on opiate agonist substitution therapy can be successfully treated with grazoprevir/elbasvir (Zepatier) – achieving cure rates similar to those of the population as a whole –

Published
28 September 2016
By
Liz Highleyman
Achillion Announces 100% SVR12 in the 6-Week and 8-Week Cohorts in Janssen’s Phase 2 Trial Evaluating the Triple Combination Treatment Regimen Including Odalasvir, AL-335, and Simeprevir for Genotype 1 Treatment-Naïve HCV

The e-poster presented at EASL / AASLD Special Conference: New Perspectives in Hepatitis C Virus Infection – The Roadmap For Cure reports that 100 percent of patients receiving treatment for as short as six weeks with a triple combination of once-daily (QD) AL-335 800mg and simeprevir (SMV) 75mg with 50mg every other day (QOD) of ODV achieved a sustained viral response 12 weeks after the completion of treatment (SVR12).

Published
26 September 2016
From
Achillion press release

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.